Theravance Biopharma, Inc. (TBPH)

NASDAQ: TBPH · IEX Real-Time Price · USD

9.17

-0.05 (-0.54%)

At close: Apr 24, 2024, 4:00 PM

8.95

-0.22 (-2.40%)

After-hours: Apr 24, 2024, 4:05 PM EDT

Theravance Biopharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 2011
Net Income	-55.19	872.13	-199.43	-278.02	-236.46	-215.52	-285.41	-190.67	-182.22	-237.04	Upgrade
Depreciation & Amortization	6.15	7.71	8.59	8.05	9.67	4.48	3.8	3.12	2.99	3.27	Upgrade
Share-Based Compensation	25.37	39.73	62.06	62.98	60.45	51.31	49.15	41.15	54.13	42.95	Upgrade
Other Operating Activities	-3.33	-1,106.56	-79.08	-43.41	-71.86	46.86	31.41	47.41	-43.75	15.66	Upgrade
Operating Cash Flow	-27	-186.99	-207.86	-250.4	-238.2	-112.87	-201.05	-98.99	-168.86	-175.16	Upgrade
Capital Expenditures	-0.98	1.29	-3.4	-6.55	-3.17	-7.22	-2.41	-2.14	-2.65	-3.11	Upgrade
Acquisitions	0	2.71	0	0	5	20	0	0	0	0	Upgrade
Change in Investments	-31.72	54.87	127.89	17.27	-84.88	163.93	-53.93	-146.1	113.69	-102.31	Upgrade
Other Investing Activities	-	1,095	-	-	-	-	-	-	-	-0.83	Upgrade
Investing Cash Flow	-32.7	1,154	124.49	10.72	-83.05	176.71	-56.33	-148.24	111.04	-106.25	Upgrade
Share Issuance / Repurchase	-198.93	-131.48	102.59	135.23	3.44	-4.24	1.66	256.71	81.39	-0.18	Upgrade
Debt Issued / Paid	0	-631.6	-10.73	144.65	-2.15	229.44	0	222.5	0	0	Upgrade
Other Financing Activities	-	4.28	-	-16.8	-	-	-	0.02	-0.08	370.8	Upgrade
Financing Cash Flow	-198.93	-758.81	91.86	263.09	1.29	225.2	1.66	479.23	81.31	370.62	Upgrade
Net Cash Flow	-258.63	208.21	8.5	23.4	-319.96	289.04	-255.73	232	23.49	89.22	Upgrade
Free Cash Flow	-27.97	-185.7	-211.26	-256.96	-241.37	-120.09	-203.46	-101.12	-171.5	-178.26	Upgrade
Free Cash Flow Margin	-48.71%	-361.66%	-381.95%	-357.59%	-328.78%	-198.92%	-1322.36%	-207.87%	-407.12%	-1525.17%	Upgrade
Free Cash Flow Per Share	-0.51	-2.52	-3.04	-4.12	-4.34	-2.23	-3.89	-2.26	-5.02	-5.61	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).